1 The aim of this study was to evaluate the potency of YM-53601 ((E)-2-[2-¯uoro-2-(quinuclidin-3-ylidene) ethoxy]-9H-carbazole monohydrochloride), a new inhibitor of squalene synthase, in reducing both plasma cholesterol and triglyceride levels, compared with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor and ®brates, respectively. 2 YM-53601 equally inhibited squalene synthase activities in hepatic microsomes prepared from several animal species and also suppressed cholesterol biosynthesis in rats (ED 50 , 32 mg kg 71 ). 3 In guinea-pigs, YM-53601 and pravastatin reduced plasma nonHDL-C (=total cholesterol ± high density lipoprotein cholesterol) by 47% (P50.001) and 33% (P50.001), respectively (100 mg kg 71 , daily for 14 days). In rhesus monkeys, YM-53601 decreased plasma nonHDL-C by 37% (50 mg kg
71, twice daily for 21 days, P50.01), whereas the HMG-CoA reductase inhibitor, pravastatin, failed to do (25 mg kg 71 , twice daily for 28 days). 4 YM-53601 caused plasma triglyceride reduction in hamsters fed a normal diet (81% decrease at 50 mg kg 71 , daily for 5 days, P50.001). In hamsters fed a high-fat diet, the ability of YM-53601 to lower triglyceride (by 73%, P50.001) was superior to that of feno®brate (by 53%, P50.001), the most potent ®brate (dosage of each drug: 100 mg kg
71, daily for 7 days). 5 This is the ®rst report that a squalene synthase inhibitor is superior to an HMG-CoA reductase inhibitor in lowering plasma nonHDL-C level in rhesus monkeys and is superior to a ®brate in signi®cantly lowering plasma triglyceride level. YM-53601 may therefore prove useful in treating hypercholesterolemia and hypertriglyceridemia in humans.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.